Concert Pharmaceuticals Inc (CNCE) Given Consensus Rating of “Buy” by Brokerages
Concert Pharmaceuticals Inc (NASDAQ:CNCE) has been given an average rating of “Buy” by the nine ratings firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $26.00.
A number of analysts have recently issued reports on the stock. BidaskClub upgraded shares of Concert Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 9th. Mizuho downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $23.00 price objective on the stock. in a report on Friday. TheStreet upgraded shares of Concert Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Monday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Concert Pharmaceuticals in a report on Friday, October 20th. Finally, UBS Group set a $34.00 price objective on shares of Concert Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 19th.
Shares of Concert Pharmaceuticals (NASDAQ CNCE) traded down $7.53 during mid-day trading on Tuesday, reaching $20.15. 3,408,205 shares of the company’s stock traded hands, compared to its average volume of 419,925. Concert Pharmaceuticals has a 52-week low of $8.61 and a 52-week high of $30.71.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a negative return on equity of 51.48% and a net margin of 62.31%. equities analysts anticipate that Concert Pharmaceuticals will post 4.1 earnings per share for the current fiscal year.
In other news, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of Concert Pharmaceuticals stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $26.65, for a total value of $34,188,112.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Value Fund L. P. Biotechnology acquired 331,916 shares of the stock in a transaction dated Thursday, October 19th. The stock was acquired at an average price of $15.84 per share, for a total transaction of $5,257,549.44. The disclosure for this purchase can be found here. 10.10% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of CNCE. Citadel Advisors LLC acquired a new position in Concert Pharmaceuticals during the second quarter worth $6,634,000. Lyon Street Capital LLC increased its holdings in Concert Pharmaceuticals by 405.5% during the second quarter. Lyon Street Capital LLC now owns 434,752 shares of the biotechnology company’s stock worth $6,065,000 after buying an additional 348,741 shares during the last quarter. Senvest Management LLC increased its holdings in Concert Pharmaceuticals by 458.8% during the third quarter. Senvest Management LLC now owns 314,629 shares of the biotechnology company’s stock worth $4,641,000 after buying an additional 258,329 shares during the last quarter. Ingalls & Snyder LLC increased its holdings in Concert Pharmaceuticals by 14.5% during the third quarter. Ingalls & Snyder LLC now owns 1,209,062 shares of the biotechnology company’s stock worth $17,834,000 after buying an additional 153,062 shares during the last quarter. Finally, QS Investors LLC acquired a new position in Concert Pharmaceuticals during the second quarter worth $1,294,000. Institutional investors and hedge funds own 65.29% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/concert-pharmaceuticals-inc-cnce-given-consensus-rating-of-buy-by-brokerages/1807367.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.